Trial Profile
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and efficacy of JNJ-28431754 in nondiabetic overweight and obese subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Obesity; Overweight
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Nov 2013 Results published in Obesity (Silver Spring, Md.).
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.